NEW YORK – Geneyx Genomex said Tuesday that it has closed a seed financing round worth approximately $6.5 million. Capri Ventures and Accenture Ventures led the round.
The firm, which is based in Herzliya, Israel, and Foster City, California, also said that it has joined Accenture Ventures’ Project Spotlight, a program that helps connect software startups with major public companies.
Geneyx, which makes an artificial intelligence-driven genetic data analysis and interpretation platform to improve risk prediction and diagnostic yield, plans to use the funding to support global growth. The firm hopes to help its users achieve 90 percent diagnostic yield within the next two years with its analysis of whole-genome sequencing data.
“The opportunity for better diagnosis and treatments spanning the continuum of health from prediction to prognosis requires more sophisticated tools for collaboration across sectors of the healthcare and biomedical research ecosystem,” Alex Pinchev, managing partner of Capri Ventures, said in a statement. “Geneyx’s AI-based software solutions have the potential to transform healthcare by enhancing diagnostic and prognostic capabilities across patient populations and democratizing biomedical research.”